Helus Pharma (R7E0) Stock Forecast & Price Target

5 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

R7E0 Analyst Ratings

Strong Buy

6 Buy

0 Hold

0 Sell

Based on 6 analysts giving stock ratings to

Helus

Pharma

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

R7E0 Stock 12 Month Forecast

Average Price Target

€36.65

▲(205.44% Upside)

Based on 6 Wall Street analysts offering 12 month price targets for Helus Pharma in the last 3 months. The average price target is €36.65 with a high forecast of €62.32 and a low forecast of €14.25. The average price target represents a 205.44% change from the last price of €12.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"€2","63":"€63","17.25":"€17.25","32.5":"€32.5","47.75":"€47.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":62.3244895,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€62.32</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":36.65273549166667,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€36.65</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.2455976,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€14.25</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,17.25,32.5,47.75,63],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.86,14.818806884615384,18.77761376923077,22.736420653846153,26.695227538461538,30.654034423076922,34.61284130769231,38.57164819230769,42.530455076923076,46.48926196153846,50.448068846153845,54.40687573076923,58.365682615384614,{"y":62.3244895,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.86,12.844056576282052,14.828113152564102,16.812169728846154,18.796226305128204,20.78028288141026,22.76433945769231,24.74839603397436,26.73245261025641,28.716509186538463,30.700565762820514,32.68462233910256,34.66867891538462,{"y":36.65273549166667,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.86,11.120430584615384,11.38086116923077,11.641291753846154,11.901722338461537,12.162152923076922,12.422583507692307,12.683014092307692,12.943444676923077,13.20387526153846,13.464305846153845,13.72473643076923,13.985167015384615,{"y":14.2455976,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.7,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.5,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.6,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.95,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.4,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.25,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.4,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.93,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.13,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.83,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.1,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.16,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.86,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€62.32

Average Price Target€36.65

Lowest Price Target€14.25

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Patrick Trucchio

H.C. Wainwright

€62.32

Buy

419.37%

Upside

Reiterated

10/22/26

Helus Pharma: Buy Rating Reiterated on HLP003 Phase 3 Upside and Pipeline Expansion; $70 Price Target Maintained

Sumant Kulkarni

Canaccord Genuity

€37.39

Buy

211.62%

Upside

Reiterated

10/22/26

Analysts Are Bullish on These Healthcare Stocks: Achieve Life Sciences (ACHV), AngioDynamics (ANGO)

Andrew Tsai

Jefferies

€19.59

Buy

63.23%

Upside

Reiterated

10/05/26

Jefferies Sticks to Their Buy Rating for Helus Pharma (HELP)

Ritu Baral

TD Cowen

€55.2

Buy

360.01%

Upside

Reiterated

09/21/26

Emily Field

Barclays

€31.16

Buy

159.69%

Upside

Initiated

09/18/26

Analysts Offer Insights on Healthcare Companies: Helus Pharma (NASDAQ: HELP), Ultragenyx Pharmaceutical (NASDAQ: RARE) and Novavax (NASDAQ: NVAX)

Benjamin Burnett

Wells Fargo

€14.25

Buy

18.71%

Upside

Reiterated

08/31/26

Analysts Offer Insights on Healthcare Companies: Capricor Therapeutics (NASDAQ: CAPR) and Helus Pharma (NASDAQ: HELP)

David Martin PhD

Bloom Burton

€41.85

Buy

248.72%

Upside

Reiterated

07/21/26

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (NYSE: JNJ), Helus Pharma (NASDAQ: HELP) and Nektar Therapeutics (NASDAQ: NKTR)

James Molloy

Alliance Global Partners

€26.71→€13.36

Buy

11.29%

Upside

Reiterated

07/14/26

Helus Pharma price target lowered to $15 from $30 at Alliance GlobalHelus Pharma price target lowered to $15 from $30 at Alliance Global

Eddie Hickman

Guggenheim

€34.72→€42.74

Buy

256.14%

Upside

Reiterated

12/03/25

Cybin price target raised to $48 from $39 at GuggenheimCybin price target raised to $48 from $39 at Guggenheim

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Patrick Trucchio

H.C. Wainwright

€62.32

Buy

419.37%

Upside

Reiterated

10/22/26

Helus Pharma: Buy Rating Reiterated on HLP003 Phase 3 Upside and Pipeline Expansion; $70 Price Target Maintained

Sumant Kulkarni

Canaccord Genuity

€37.39

Buy

211.62%

Upside

Reiterated

10/22/26

Analysts Are Bullish on These Healthcare Stocks: Achieve Life Sciences (ACHV), AngioDynamics (ANGO)

Andrew Tsai

Jefferies

€19.59

Buy

63.23%

Upside

Reiterated

10/05/26

Jefferies Sticks to Their Buy Rating for Helus Pharma (HELP)

Ritu Baral

TD Cowen

€55.2

Buy

360.01%

Upside

Reiterated

09/21/26

Emily Field

Barclays

€31.16

Buy

159.69%

Upside

Initiated

09/18/26

Analysts Offer Insights on Healthcare Companies: Helus Pharma (NASDAQ: HELP), Ultragenyx Pharmaceutical (NASDAQ: RARE) and Novavax (NASDAQ: NVAX)

Benjamin Burnett

Wells Fargo

€14.25

Buy

18.71%

Upside

Reiterated

08/31/26

Analysts Offer Insights on Healthcare Companies: Capricor Therapeutics (NASDAQ: CAPR) and Helus Pharma (NASDAQ: HELP)

David Martin PhD

Bloom Burton

€41.85

Buy

248.72%

Upside

Reiterated

07/21/26

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (NYSE: JNJ), Helus Pharma (NASDAQ: HELP) and Nektar Therapeutics (NASDAQ: NKTR)

James Molloy

Alliance Global Partners

€26.71→€13.36

Buy

11.29%

Upside

Reiterated

07/14/26

Helus Pharma price target lowered to $15 from $30 at Alliance GlobalHelus Pharma price target lowered to $15 from $30 at Alliance Global

Eddie Hickman

Guggenheim

€34.72→€42.74

Buy

256.14%

Upside

Reiterated

12/03/25

Cybin price target raised to $48 from $39 at GuggenheimCybin price target raised to $48 from $39 at Guggenheim

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

PTGXProtagonist Therapeutics

SIBNSI-Bone

IMUXImmunic

MDWDMediwound

HROWHarrow Health

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Helus Pharma

3 Months

Sumant KulkarniCanaccord Genuity

Success Rate

10/21 ratings generated profit

Average Return

+4.32%

Copying Sumant Kulkarni's trades and holding each position for 3 Months would result in 47.62% of your transactions generating a profit, with an average return of +4.32% per trade.

1 Year

Patrick TrucchioH.C. Wainwright

Success Rate

9/16 ratings generated profit

Average Return

+25.61%

Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 56.25% of your transactions generating a profit, with an average return of +25.61% per trade.

2 Years

David Martin PhDBloom Burton

Success Rate

6/7 ratings generated profit

Average Return

+28.59%

Copying David Martin PhD's trades and holding each position for 2 Years would result in 85.71% of your transactions generating a profit, with an average return of +28.59% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

R7E0 Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, R7E0 has received 12 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. R7E0 average Analyst price target in the past 3 months is 36.65.

Each month's total comprises the sum of three months' worth of ratings.

R7E0 Financial Forecast

R7E0 Earnings Forecast

Next quarter’s earnings estimate for R7E0 is -€0.62 with a range of -€0.81 to -€0.37. The previous quarter’s EPS was -€0.80. R7E0 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year R7E0 has Performed in-line its overall industry.

No data currently available

R7E0 Sales Forecast

Next quarter’s sales forecast for R7E0 is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. R7E0 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year R7E0 has Performed in-line its overall industry.

R7E0 Stock Forecast FAQ

What is DE:R7E0’s average 12-month price target, according to analysts?

Based on analyst ratings, Helus Pharma’s 12-month average price target is 36.65.

What is DE:R7E0’s upside potential, based on the analysts’ average price target?

Helus Pharma has 205.44% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Helus Pharma a Buy, Sell or Hold?

Helus Pharma has a consensus rating of Strong Buy, which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.

What is Helus Pharma’s share price target?

The average share price target for Helus Pharma is 36.65. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €62.32 ,and the lowest forecast is €14.25. The average share price target represents 205.44% Increase from the current price of €12.

What do analysts say about Helus Pharma?

Helus Pharma’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of Helus Pharma?

To buy shares of DE:R7E0, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Helus Pharma (R7E0) Stock Forecast & Price Target

R7E0 Analyst Ratings

R7E0 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Helus Pharma

R7E0 Analyst Recommendation Trends

R7E0 Financial Forecast

R7E0 Earnings Forecast

R7E0 Sales Forecast

R7E0 Stock Forecast FAQ

Detailed List of Analyst Forecasts